Background
The Gleason score (GS) is an established prostate cancer (PCa) prognostic factor. Whether the presence of differing GS’s at biopsy (e.g. 4 + 3 and 3 + 3), which we term ComboGS, improves the prognosis that would be predicted based on the highest GS (e.g.4 + 3) due to decreased upgrading is unknown. Therefore, we evaluated the odds of upgrading at radical prostatectomy (RP) and the risk of prostate cancer-specific mortality (PCSM) when ComboGS was present versus absent.
Methods
Logistic and competing risks regression were performed to assess the impact ComboGS had on the odds of upgrading at RP in the index (n=134) and validation cohorts (n=356) and the risk of PCSM following definitive therapy in a long-term cohort (n=666), adjusting for known predictors of these endpoints. We calculated and compared the area under the curve using a receiver operating characteristic analysis when ComboGS was included versus excluded from the upgrading models.
Results
ComboGS was associated with decreased odds of upgrading (Index: Adjusted Odds Ratio (AOR): 0.14 [95% CI: 0.04–0.50], p = 0.003; Validation: AOR: 0.24 [95%CI: 0.11–0.51], p< 0.001) and added significantly to the predictive value of upgrading for the in-sample index (p = 0.02), validation (p = 0.003) and out-of-sample prediction models (p = 0.002). ComboGS was also associated with a decreased risk of PCSM (AHR: 0.40 [95% CI: 0.19–0.85], p= 0.02).
Conclusions
Differing biopsy Gleason scores are associated with both a lower odds of upgrading and risk of PCSM. If validated, future randomized non-inferiority studies evaluating de-escalated treatment approaches in men with ComboGS could be considered.